Oyster_Point_Social.jpg
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference
December 29, 2020 16:01 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
December 18, 2020 07:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers
December 07, 2020 07:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
December 01, 2020 16:01 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 25, 2020 09:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
November 13, 2020 07:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights
November 05, 2020 16:01 ET | Oyster Point Pharma, Inc.
OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease Remains on Track for Q4 2020OC-01 Investigational New Drug (IND)...
Oyster_Point_Social.jpg
Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020
October 29, 2020 16:01 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth
October 08, 2020 16:01 ET | Oyster Point Pharma, Inc.
Ali Behbahani, M.D. takes on role of Chairperson of the Board Michael G. Atieh joins the Board of Directors as Chairperson of the Audit Committee PRINCETON, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE)...
Oyster_Point_Social.jpg
Oyster Point Pharma to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
September 11, 2020 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...